Literature DB >> 11370266

Menkes disease after copper histidine replacement therapy: case report.

D H George1, R E Casey.   

Abstract

Menkes disease (MD) is an X-linked recessive disorder of copper metabolism, characterized in its untreated state by progressive disorders of multiple systems, especially the central nervous system (CNS) and connective tissue, and death by 3 years of age. Recently, therapy with copper-histidine has modified the severity of MD and permitted survival into adolescence. Clinical response has been greater for the neurological abnormalities than for the connective tissue abnormalities. In this report, we describe the postmortem pathology of one individual who had received copper-histidine therapy and died at age 10; we believe this to be the first such pathological report. The postmortem examination demonstrated significant pathology of mesenchymal tissues, including skeletal abnormalities, vascular degeneration, and bladder diverticula. The CNS, by contrast, showed minimal pathology. The phenotype was more consistent with occipital horn syndrome, a milder allelic disorder of copper metabolism, than with classic MD. The differential sensitivity of CNS and mesenchymal tissues to copper-histidine therapy may result from heterogeneity in the response of different copper-dependent enzymes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11370266     DOI: 10.1007/s100240010142

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  2 in total

1.  Identification of a novel mutation in the ATP7A gene in a Korean patient with Menkes disease.

Authors:  Yong Hyuk Kim; Ran Lee; Han Wook Yoo; Mi-Sun Yum; Sun Hwan Bae; So Chung Chung; Yong Mean Park; Jae Sung Son
Journal:  J Korean Med Sci       Date:  2011-06-20       Impact factor: 2.153

2.  Long-term skeletal findings in Menkes disease.

Authors:  Eva Amador; Ruth Domene; Cristian Fuentes; Juan-Carlos Carreño; Goya Enríquez
Journal:  Pediatr Radiol       Date:  2010-02-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.